News
Article
Author(s):
The ad is the latest DTC content from SK Life Science.
Stock.adobe.com
SK Life Science launched its latest DTC advertising campaign for its seizure medication.1 Road to Reduction is an educational campaign that promotes seizure medication XCORPI, along with awareness for epilepsy and the importance of patients actively seeking out conversations with their doctors about treatments to reduce seizures.
Campaigns like this allow companies like SK Life Sciences to reach a patient population directly. This allows the message to be tailored to the specific needs of the population. When it comes to seizure control, patients suffering from epilepsy often struggle with isolation and fear. This particular campaign aims to reduce those feelings and empower patients to seek out treatments and work towards a seizure-free life.
In a press release, SK Life Science executive director Chris Fanale said, “At SK Life Science, we've always been committed to elevating the voices of people living with epilepsy and advocating for patient voices to be heard when choosing a treatment option. This campaign reflects a deeply authentic understanding of what patients and caregivers face daily––and encourages them to talk with their doctors about options that may help reduce seizures, even in people who have been living with uncontrolled seizures for a long time."
SK Life Science has taken other steps to promote awareness around seizures. In March of last year, the company participated in Purple Day, an annual event for epilepsy awareness that provides education about potential tools and treatments for people living with the disease.2
In a press release issued at the time, SK Life Science’s chief commercial officer Matt Linkewich said, “SK Life Science is celebrating Purple Day activities for the seventh consecutive year. We remain committed to delivering impactful resources that equip the epilepsy community with the information and tools they need to feel empowered in their epilepsy journey. It is estimated that 3.4 million people in the U.S. are living with epilepsy, and we hope these tools will encourage and support patients and caregivers and help remove some of the barriers to epilepsy treatment."
In the same press release, Louis Ferrari, BS, RPh, MBA, vice president of medical affairs at SK Life Science, added, “At SK Life Science, we are proud to support organizations that provide the patient community with accessible educational resources on epilepsy and ways to manage seizures. We share their commitment to empower those living with epilepsy and their loved ones with resources that will inspire more informed discussions among patients, caregivers, and their healthcare providers."
The company also announced the publication of a sponsored supplement to leading epilepsy journal Epilepsia in March.3 The content focused on ways for people living with epilepsy to improve their lives.
Patrick Kwan, PhD, FRACP, and professor of neurology at Monash University in Melbourne, Australia, co-edited the content. In a press release issued at the time, he said, “Today, with the approval of newer medicines that have demonstrated impressive efficacy and safety, long-term seizure freedom is more possible than ever for people with drug-resistant epilepsy. Yet, these medicines are underutilized or not introduced when they could have the greatest impact. With some newer agents not yet included in professional treatment guidelines, this collection of articles provides clinicians with a comprehensive review of relevant data and practical strategies to proactively incorporate and manage innovative antiseizure medications earlier in treatment."
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
